Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2009
02/19/2009WO2008111590A3 Ampa and nmda receptor antagonists for neurodegenerative diseases
02/19/2009WO2008109856A3 Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions
02/19/2009WO2008109547A4 Nucleic acid compounds for inhibiting tymp gene expression and uses thereof
02/19/2009WO2008109506A9 Nucleic acid compounds for inhibiting jun gene expression and uses thereof
02/19/2009WO2008109450A9 Nucleic acid compounds for inhibiting id-1 gene expression and uses thereof
02/19/2009WO2008109352A4 Nucleic acid compounds for inhibiting akt gene expression and uses thereof
02/19/2009WO2008109350A3 Nucleic acid compounds for inhibiting il6 gene expression and uses thereof
02/19/2009WO2008106128A3 CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
02/19/2009WO2008101029A3 Use of thiazole, oxazole and imidazole compounds for the treatment of sodium channel-mediated diseases or conditions
02/19/2009WO2008100560A3 Estrogen receptor modulators, associated pharmaceutical compositions and methods of use
02/19/2009WO2008094319A3 Methods and compositions of trail-death receptor agonists/activators
02/19/2009WO2008079787A3 Glucokinase activators
02/19/2009WO2008063842A3 Methods of treating neuropathic pain with agonists of ppar-gamma
02/19/2009WO2008060766A3 Histamine h4 receptor ligands for use in pain treatment
02/19/2009WO2008057246A3 Method for treating inflammatory disorders
02/19/2009WO2008046083A3 Use of oxindole compounds as therapeutic agents
02/19/2009WO2008042892A3 Fatty acid amide hydrolase inhibitors for energy metabolism disorders
02/19/2009WO2008033754A3 Xanthine derivatives in methods and compositions for the treatment of vascular depression
02/19/2009WO2008018827A8 Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
02/19/2009WO2008017753A3 Pharmaceutical composition containing saredutant and a selective inhibitor of serotonin recapture or an inhibitor of serotonin/norepinephrine recapture in combination
02/19/2009WO2008011992A8 Camptothecin derivatives with antitumor activity
02/19/2009WO2008008854A8 Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
02/19/2009WO2007121483A3 Pre-mixed, ready-to-use iv bolus compositions and methods of use
02/19/2009WO2007095389A3 Treatment of hyperproliferative diseases with camptothecine n-oxide and analogs
02/19/2009WO2007078895A3 Modified release formulations of tramadol and uses thereof
02/19/2009WO2007075772A3 Compounds, screens, and methods of treatment
02/19/2009WO2006065484A3 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
02/19/2009WO2006030301A4 Cilostazol- containing pharmaceutical composition based on particles of less than 50 micrometers
02/19/2009WO2006029173A3 Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12
02/19/2009WO2005096784A3 Benzotriazine inhibitors of kinases
02/19/2009WO2003097072A9 Chloasma amelioration composition and dullness amelioration composition
02/19/2009US20090048579 Method and apparatus for dispensing a composition
02/19/2009US20090048461 Regulators of Bacterial Signalling Pathways
02/19/2009US20090048447 Method for decreasing opioid metabolism
02/19/2009US20090048442 Novel compounds
02/19/2009US20090048412 Complexes between an amphiphilic polymer and an osteogenic protein belonging to the family of BMPs
02/19/2009US20090048349 Compositions and kits for compounding pharmaceuticals
02/19/2009US20090048348 Method for treating autism
02/19/2009US20090048347 Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic
02/19/2009US20090048346 Therapeutic formulations
02/19/2009US20090048345 Immediate release and sustained release ibuprofen dosing regimen
02/19/2009US20090048344 Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid
02/19/2009US20090048343 Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field
02/19/2009US20090048342 Combination of Bioavailable Methionine With at Least One Essential Oil
02/19/2009US20090048341 Oral administering; controlling blood concentration; sustained release; urogenital disorders; blood disorders
02/19/2009US20090048340 Growth hormone secretion regulator
02/19/2009US20090048339 Compositions of cis-9, trans-11 conjugated linoleic acid and vaccenic acid and uses thereof
02/19/2009US20090048338 Biologically active oils
02/19/2009US20090048337 Modulation of anxiety through blockade of anandamide hydrolysis
02/19/2009US20090048336 Escitalopram oxalate powders
02/19/2009US20090048335 Process for preparing simvastatin
02/19/2009US20090048334 Sodium ascorbate solubilisate
02/19/2009US20090048333 Zearalenone Macrolide Derivatives and Uses of the Same
02/19/2009US20090048332 Natural Novel Antioxidants
02/19/2009US20090048331 Methods and formulations for the delivery of pharmacologically active agents
02/19/2009US20090048330 Compound from Antrodia camphorata and the use thereof
02/19/2009US20090048329 Substituted Pyrrolidine Compounds With Central Nervous System Activity
02/19/2009US20090048328 Compound Comprising Prodigiosin From Serratia Macescence B-1231 Kctc 0386Bp for Prevention and Treatment of Acute Graft-Versus-Host Disease
02/19/2009US20090048327 Polymorphs of Pyrrole Substituted 2-Indolinone Protein Kinase Inhibitors
02/19/2009US20090048326 Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
02/19/2009US20090048325 Prophylactic or Therapeutic Agent for Irritable Bowel Syndrome
02/19/2009US20090048324 Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
02/19/2009US20090048323 such as 1-cyclohexyl-5-{4-[dimethylamino-(3-fluorophenyl)-methyl]-cyclohexyl}-4-isobutyl-4,5-dihydro-1H-imidazole-4-carboxylic acid methyl ester, used to treat pain, depression, urinary incontinence, diarrhea, pruritus, alcohol and drug misuse, drug dependency, lethargy and/or anxiety
02/19/2009US20090048322 Parenteral and oral formulations of benzimidazoles
02/19/2009US20090048321 Benzimidazole Derivatives and Their Use for Modulating the GABA-Alpha Receptor Complex
02/19/2009US20090048320 Used to treat beta -amyloid deposits and neurofibrillary tangles, including Alzheimer's disease, Trisomy 21 (Down's Syndrome), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-type (HCHWA-D), and other neurodegenerative disorders.
02/19/2009US20090048318 Methods for treating degenerative diseases/injuries
02/19/2009US20090048317 Formulations of candesartan
02/19/2009US20090048316 Pharmaceutical composition comprising candesartan cilexetil
02/19/2009US20090048315 Administering glutaminase inhibitor to a subject suffering from chronic pain at a site of inflammation for therapy of chronic pain
02/19/2009US20090048314 Treatment of duchenne muscular dystrophy
02/19/2009US20090048313 enzyme synthetase, ligase and/or kinase inhibitors such as N-(3-(diethylamino)propyl)-N-(4-(2,5-dimethoxyphenyl)thiazol-2-yl)benzamide, used for treating Alzheimer's disease, strokes, diabetes, obesity, inflammation, cancer and rheumatoid arthritis
02/19/2009US20090048310 Agent for prevention/treatment of disease caused by acyclovir-resistant herpesvirus
02/19/2009US20090048308 VLA-4 Antagonists
02/19/2009US20090048307 5-pyridyl-1, 3-azole compounds, process for producing the same and use there of
02/19/2009US20090048306 Pyridine derivatives
02/19/2009US20090048305 Antimicrobial ortho-Fluorophenyl Oxazolidinones For Treatment of Bacterial Infections
02/19/2009US20090048304 Crystal Form of Besipirdine Chlorhydrate, Process Preparation and Use Thereof
02/19/2009US20090048303 Indole-2-carboxamidine derivatives as nmda receptor antago
02/19/2009US20090048302 Methods and compositions for the treatment of conditions related to gastric acid secretion
02/19/2009US20090048301 Heterocyclic compounds and their use as anticancer agents
02/19/2009US20090048300 Heterocyclic Compounds
02/19/2009US20090048299 Biphenyl compounds useful as muscarinic receptor antagonists
02/19/2009US20090048298 Novel acetyl-CoA Carboxylase (ACC) Inhibitors and their use in Diabetes, Obesity and Metabolic Syndrome
02/19/2009US20090048297 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
02/19/2009US20090048296 High concentration local anesthetic formulations
02/19/2009US20090048295 Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof
02/19/2009US20090048294 Hif-1 alpha activating agent
02/19/2009US20090048293 Methods for treating bacillus infection
02/19/2009US20090048292 Synergistic combination
02/19/2009US20090048291 Novel Piperidine-4-Acetic Acid Derivatives and Their Use
02/19/2009US20090048290 2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl-benzyofuran-2-carboxamide, novel salt forms, and methods of use thereof
02/19/2009US20090048289 Administration of tropisetron for treating inflammatory skin diseases/disorders
02/19/2009US20090048288 Method of treating stress-mediated depression
02/19/2009US20090048287 Compositions useful for treating gastrointestinal motility disorders
02/19/2009US20090048286 Inhibitors of Protein Tyrosine Phosphatase 1B
02/19/2009US20090048285 Pyrrolopyridines Useful in the Treatment of Inflammation
02/19/2009US20090048284 Therapeutic compounds
02/19/2009US20090048283 Salt of an androgen receptor modulator
02/19/2009US20090048282 Pyrimidine sulfonamide analogs and their use as agonists of the wnt-beta-catenin cellular messaging system